Drug Trial Radar · NCT07263438
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
59
Planned (sponsor's estimate)
Start
Nov 3, 2025
Primary completion
Mar 30, 2028
Study completion Dec 31, 2030
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire VaudoisAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentric phase II open-label clinical trial aiming to assess the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma. Eligible patients will be assigned to two cohorts depending on whether there is a medical indication for a neurosurgical resection from first recurrent tumor or not. The aim of the cohort 1 (patients without indication for surgery) is to analyze the clinical efficacy of this triple combination in recurrent glioblastoma. 48 patients will be registered. The aim of cohort 2 (patients with indication for surgery) is to confirm the level of trimipramine that can be achieved in the tumor tissue and cerebrospinal fluid collected during surgery. At least 5 patients will be registered. All patients will receive the combination treatment (trimipramine and atezolizumab associated with bevacizumab) for a maximum period of 2 years from registration. The treatment schedule is slightly different for the 2 cohorts because of the neurosurgical resection foreseen for cohort 2 and the requirement to start bevacizumab only after the surgery. After the end of treatment, all patients will be followed up for safety during 90 days from first treatment administration and then up to 3 years from registration.
Conditions
- Glioblastoma
- Recurrence Tumor
Interventions
TrimipramineDrug
Trimipramine: daily oral intake at 75mg/ day for 7 days, then at 150 mg/ day
Cohort 1: AtezolizumabBiological
Atezolizumab: intravenous administration at 1200 mg on the first day of 3-week cycles.
BevacizumabBiological
Bevacizumab will be administered intravenously at 15 mg/kg on the first day of 3-week cycles.
Cohort 2: AtezolizumabBiological
Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on the first day of 3-week cycles. Administration will occur once, then will be interrupted during a recovery period of 14-days post surgery, and then resumed.
Cohort 2: BevacizumabBiological
Bevacizumab will be administered intravenously at 15 mg/kg on the first day of 3-week cycles. The first administration will take place 5 weeks after surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1: Progression-free survival rate [PFSR]Time frame: 6 months after last patient's registration
- Cohort 2: Level of trimipramine in the tumor tissue and cerebrospinal fluid [CSF]Time frame: 3 months after last patient's surgery
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Universitätsspital Basel
Basel, Basel, Switzerland · Recruiting
Kantonsspital Aarau
Aarau, Canton of Aargau, Switzerland · Recruiting
Bern Inselspital
Bern, Canton of Bern, Switzerland · Recruiting
HFR Fribourg - Hôpital cantonal
Fribourg, Canton of Fribourg, Switzerland · Recruiting
Luzerner Kantonsspital
Lucerne, Canton of Lucerne, Switzerland · Recruiting
Centre Hospitalier Universitaire Vaudois
Lausanne, Canton of Vaud, Switzerland · Recruiting
Universitätsspital Zürich
Zurich, Canton of Zurich, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.